MASLD Cirrhosis: From Diagnosis to Transplant

MASLD Cirrhosis: From Diagnosis to Transplant

Comprehensive Clinical Summary

1. Main Clinical Topics Discussed

• Epidemiology and public health burden of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), formerly NAFLD/NASH
• Non-invasive diagnostic and fibrosis staging strategies across the care continuum
• Risk stratification tools including FIB-4, fibroscan, and composite scores (AGILE 3+, AGILE 4)
• Gaps in primary care recognition and referral pathways
• Prognostic implications of fibrosis stage, including progression to cirrhosis and liver transplantation
• The patient journey across three key disease milestones: asymptomatic disease → advanced fibrosis → liver transplantation

2. Key Learning Points, Guidelines, and Recommendations

Terminology:

• "MASLD" (Metabolic dysfunction-Associated Steatotic Liver Disease) replaces "NAFLD/NASH" per updated international consensus nomenclature
• "MASH" (Metabolic dysfunction-Associated SteatoHepatitis) replaces "NASH"

Disease Staging Framework:

• Three clinically relevant milestones:

1. Asymptomatic disease – majority of patients, managed in primary care/endocrinology

2. Advanced fibrosis (F3–F4) – "at-risk" population requiring hepatology involvement

3. Cirrhosis with decompensation – candidates for liver transplant evaluation

Non-Invasive Testing (NIT) Strategy (per AASLD guidelines):

• FIB-4 is the recommended first-line risk stratification tool, applicable in primary care
• Indeterminate or high FIB-4 scores → proceed to fibroscan or ELF test; refer to hepatology if fibroscan unavailable
• AGILE 3+ and AGILE 4 scores (combining clinical, laboratory, and elastography data) improve specificity for classifying F3 and F4 disease, helping move patients out of the indeterminate range
• Liver biopsy should be targeted — reserved for patients likely to have MASH with advanced fibrosis or where competing diagnoses cannot be excluded

Shared Care Model:

• Management of at-risk MASLD patients requires collaboration between hepatology and primary care, with concurrent focus on liver disease and cardiometabolic risk reduction

3. Specific Clinical Data, Statistics, and Study Results Cited

Epidemiology:

• MASLD affects 25–30% of the U.S. population and approximately 30% of the global population
• Among patients with diabetes: prevalence of MASLD is 40–70%
• 30% of MASLD patients have the more progressive form (MASH)
• Up to 20% of MASLD patients may have advanced fibrosis or cirrhosis; those with diabetes are at highest risk

FIB-4 Performance:

• C-statistic generally ≥0.80 in validated hepatology clinic populations
• In a safety-net clinic cohort (San Francisco, ~350 patients) with diabetes: C-statistic dropped to 0.68 for ruling out advanced fibrosis vs. 0.85 in non-diabetic populations
• Age-specific cut-off: a threshold of 2.0 (vs. 1.3) proposed for patients >65 years to maintain specificity

UCSF Primary Care Screening Study (~27,000 patients):

• 3,300 patients had diabetes; FIB-4/NFS calculable in >3,000
• Nearly one-third had a high fibrosis score by FIB-4 and/or NAS fibrosis score
• Among high-risk patients referred to hepatology: 87% confirmed to have MASLD; 36% ultimately diagnosed with F3–F4 disease

Primary Care Provider Survey (UCSF):

• 36% of PCPs were unsure how to diagnose MASLD
• 50% lacked sufficient confidence to definitively diagnose MASLD
• Only 18% were aware of and regularly using FIB-4
• In a Cornell